Outcome measures for pediatric spinal muscular atrophy

Susan T. Iannaccone, Karen Rabb, Deanna Carman, Jennifer Gordon, Kathalene Harris, Anne Morton, Linda Hynan, Joan Reisch, Janet Smith, Joe C. Webster, Peter Schochet, Peter Luckett, Laura Herbelin, Brenda Wong, Fred Samaha, Ann Fritch, Barry Russman, Kirsten Zilke, Robert Leshner, Jill MayhewStephen Smith, Jean Louis Stout

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Spinal muscular atrophy (SMA) is a genetic disease of the anterior horn cell with a frequency of 8 per 100000 live births and a high rate of mortality during infancy. The American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group is an organization of 5 centers formed to perform clinical trials in children with SMA. Objective: To devise reliable methods to measure strength, motor function, lung function, and quality of life for use as outcome measures in children with SMA. Setting: Tertiary referral center, pediatric neurology department. Patients and Methods: Twelve children with SMA aged 2 to 14 years were enrolled in a reliability study of 4 outcome measures: quantitative muscle testing (in children >5 years), gross motor function measure, pulmonary function tests, and quality of life. The Richmond Quantitative Measurement System was used to test grip, knee flexion and extension, and elbow flexion. Gross motor function measure was performed as described, and pulmonary function tests were measured using the KoKo system. Quality of life was assessed via the PedsQL and the PedsQL Neuromuscular Module for patients and parents. Results: Ten children fulfilled the inclusion criteria and completed at least 3 visits with 3 evaluators in 6 months. Using a weighted κ, the gross motor function measure showed high interrater reliability. Quantitative muscle testing showed greater variability among the weakest children; the findings for pulmonary function tests and quality of life were inconclusive. The PedsQL Neuromuscular Module for parents had moderately high reliability. Conclusion: A tool for motor function may be more useful in clinical trials of childhood SMA than one for quantitative muscle strength.

Original languageEnglish (US)
Pages (from-to)1445-1450
Number of pages6
JournalArchives of Neurology
Volume59
Issue number9
DOIs
StatePublished - Sep 2002

Fingerprint

Spinal Muscular Atrophy
Outcome Assessment (Health Care)
Pediatrics
Respiratory Function Tests
Quality of Life
Parents
Clinical Trials
Spinal Muscular Atrophies of Childhood
Anterior Horn Cells
Muscles
Inborn Genetic Diseases
Live Birth
Muscle Strength
Hand Strength
Neurology
Elbow
Tertiary Care Centers
Knee
Organizations
Lung

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Iannaccone, S. T., Rabb, K., Carman, D., Gordon, J., Harris, K., Morton, A., ... Stout, J. L. (2002). Outcome measures for pediatric spinal muscular atrophy. Archives of Neurology, 59(9), 1445-1450. https://doi.org/10.1001/archneur.59.9.1445

Outcome measures for pediatric spinal muscular atrophy. / Iannaccone, Susan T.; Rabb, Karen; Carman, Deanna; Gordon, Jennifer; Harris, Kathalene; Morton, Anne; Hynan, Linda; Reisch, Joan; Smith, Janet; Webster, Joe C.; Schochet, Peter; Luckett, Peter; Herbelin, Laura; Wong, Brenda; Samaha, Fred; Fritch, Ann; Russman, Barry; Zilke, Kirsten; Leshner, Robert; Mayhew, Jill; Smith, Stephen; Stout, Jean Louis.

In: Archives of Neurology, Vol. 59, No. 9, 09.2002, p. 1445-1450.

Research output: Contribution to journalArticle

Iannaccone, ST, Rabb, K, Carman, D, Gordon, J, Harris, K, Morton, A, Hynan, L, Reisch, J, Smith, J, Webster, JC, Schochet, P, Luckett, P, Herbelin, L, Wong, B, Samaha, F, Fritch, A, Russman, B, Zilke, K, Leshner, R, Mayhew, J, Smith, S & Stout, JL 2002, 'Outcome measures for pediatric spinal muscular atrophy', Archives of Neurology, vol. 59, no. 9, pp. 1445-1450. https://doi.org/10.1001/archneur.59.9.1445
Iannaccone, Susan T. ; Rabb, Karen ; Carman, Deanna ; Gordon, Jennifer ; Harris, Kathalene ; Morton, Anne ; Hynan, Linda ; Reisch, Joan ; Smith, Janet ; Webster, Joe C. ; Schochet, Peter ; Luckett, Peter ; Herbelin, Laura ; Wong, Brenda ; Samaha, Fred ; Fritch, Ann ; Russman, Barry ; Zilke, Kirsten ; Leshner, Robert ; Mayhew, Jill ; Smith, Stephen ; Stout, Jean Louis. / Outcome measures for pediatric spinal muscular atrophy. In: Archives of Neurology. 2002 ; Vol. 59, No. 9. pp. 1445-1450.
@article{aed1d182ca0b44879e823585a8cd2159,
title = "Outcome measures for pediatric spinal muscular atrophy",
abstract = "Background: Spinal muscular atrophy (SMA) is a genetic disease of the anterior horn cell with a frequency of 8 per 100000 live births and a high rate of mortality during infancy. The American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group is an organization of 5 centers formed to perform clinical trials in children with SMA. Objective: To devise reliable methods to measure strength, motor function, lung function, and quality of life for use as outcome measures in children with SMA. Setting: Tertiary referral center, pediatric neurology department. Patients and Methods: Twelve children with SMA aged 2 to 14 years were enrolled in a reliability study of 4 outcome measures: quantitative muscle testing (in children >5 years), gross motor function measure, pulmonary function tests, and quality of life. The Richmond Quantitative Measurement System was used to test grip, knee flexion and extension, and elbow flexion. Gross motor function measure was performed as described, and pulmonary function tests were measured using the KoKo system. Quality of life was assessed via the PedsQL and the PedsQL Neuromuscular Module for patients and parents. Results: Ten children fulfilled the inclusion criteria and completed at least 3 visits with 3 evaluators in 6 months. Using a weighted κ, the gross motor function measure showed high interrater reliability. Quantitative muscle testing showed greater variability among the weakest children; the findings for pulmonary function tests and quality of life were inconclusive. The PedsQL Neuromuscular Module for parents had moderately high reliability. Conclusion: A tool for motor function may be more useful in clinical trials of childhood SMA than one for quantitative muscle strength.",
author = "Iannaccone, {Susan T.} and Karen Rabb and Deanna Carman and Jennifer Gordon and Kathalene Harris and Anne Morton and Linda Hynan and Joan Reisch and Janet Smith and Webster, {Joe C.} and Peter Schochet and Peter Luckett and Laura Herbelin and Brenda Wong and Fred Samaha and Ann Fritch and Barry Russman and Kirsten Zilke and Robert Leshner and Jill Mayhew and Stephen Smith and Stout, {Jean Louis}",
year = "2002",
month = "9",
doi = "10.1001/archneur.59.9.1445",
language = "English (US)",
volume = "59",
pages = "1445--1450",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Outcome measures for pediatric spinal muscular atrophy

AU - Iannaccone, Susan T.

AU - Rabb, Karen

AU - Carman, Deanna

AU - Gordon, Jennifer

AU - Harris, Kathalene

AU - Morton, Anne

AU - Hynan, Linda

AU - Reisch, Joan

AU - Smith, Janet

AU - Webster, Joe C.

AU - Schochet, Peter

AU - Luckett, Peter

AU - Herbelin, Laura

AU - Wong, Brenda

AU - Samaha, Fred

AU - Fritch, Ann

AU - Russman, Barry

AU - Zilke, Kirsten

AU - Leshner, Robert

AU - Mayhew, Jill

AU - Smith, Stephen

AU - Stout, Jean Louis

PY - 2002/9

Y1 - 2002/9

N2 - Background: Spinal muscular atrophy (SMA) is a genetic disease of the anterior horn cell with a frequency of 8 per 100000 live births and a high rate of mortality during infancy. The American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group is an organization of 5 centers formed to perform clinical trials in children with SMA. Objective: To devise reliable methods to measure strength, motor function, lung function, and quality of life for use as outcome measures in children with SMA. Setting: Tertiary referral center, pediatric neurology department. Patients and Methods: Twelve children with SMA aged 2 to 14 years were enrolled in a reliability study of 4 outcome measures: quantitative muscle testing (in children >5 years), gross motor function measure, pulmonary function tests, and quality of life. The Richmond Quantitative Measurement System was used to test grip, knee flexion and extension, and elbow flexion. Gross motor function measure was performed as described, and pulmonary function tests were measured using the KoKo system. Quality of life was assessed via the PedsQL and the PedsQL Neuromuscular Module for patients and parents. Results: Ten children fulfilled the inclusion criteria and completed at least 3 visits with 3 evaluators in 6 months. Using a weighted κ, the gross motor function measure showed high interrater reliability. Quantitative muscle testing showed greater variability among the weakest children; the findings for pulmonary function tests and quality of life were inconclusive. The PedsQL Neuromuscular Module for parents had moderately high reliability. Conclusion: A tool for motor function may be more useful in clinical trials of childhood SMA than one for quantitative muscle strength.

AB - Background: Spinal muscular atrophy (SMA) is a genetic disease of the anterior horn cell with a frequency of 8 per 100000 live births and a high rate of mortality during infancy. The American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group is an organization of 5 centers formed to perform clinical trials in children with SMA. Objective: To devise reliable methods to measure strength, motor function, lung function, and quality of life for use as outcome measures in children with SMA. Setting: Tertiary referral center, pediatric neurology department. Patients and Methods: Twelve children with SMA aged 2 to 14 years were enrolled in a reliability study of 4 outcome measures: quantitative muscle testing (in children >5 years), gross motor function measure, pulmonary function tests, and quality of life. The Richmond Quantitative Measurement System was used to test grip, knee flexion and extension, and elbow flexion. Gross motor function measure was performed as described, and pulmonary function tests were measured using the KoKo system. Quality of life was assessed via the PedsQL and the PedsQL Neuromuscular Module for patients and parents. Results: Ten children fulfilled the inclusion criteria and completed at least 3 visits with 3 evaluators in 6 months. Using a weighted κ, the gross motor function measure showed high interrater reliability. Quantitative muscle testing showed greater variability among the weakest children; the findings for pulmonary function tests and quality of life were inconclusive. The PedsQL Neuromuscular Module for parents had moderately high reliability. Conclusion: A tool for motor function may be more useful in clinical trials of childhood SMA than one for quantitative muscle strength.

UR - http://www.scopus.com/inward/record.url?scp=0036717349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036717349&partnerID=8YFLogxK

U2 - 10.1001/archneur.59.9.1445

DO - 10.1001/archneur.59.9.1445

M3 - Article

C2 - 12223032

AN - SCOPUS:0036717349

VL - 59

SP - 1445

EP - 1450

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -